These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 8524946)
41. Effect of methylguanidine, guanidine and structurally related compounds on constitutive and inducible nitric oxide synthase activity. Sorrentino R; Sautebin L; Pinto A Life Sci; 1997; 61(13):1283-91. PubMed ID: 9324070 [TBL] [Abstract][Full Text] [Related]
42. Reversibility of inhibition of human type II nitric oxide synthase. Nicholls DJ; Kirk A; Wallace AV Biochem Soc Trans; 1996 Feb; 24(1):20S. PubMed ID: 8674663 [No Abstract] [Full Text] [Related]
43. Acetamidine lysine derivative, N-(5(S)-amino-6,7-dihydroxyheptyl)ethanimidamide dihydrochloride: a highly selective inhibitor of human inducible nitric oxide synthase. Hallinan EA; Tsymbalov S; Finnegan PM; Moore WM; Jerome GM; Currie MG; Pitzele BS J Med Chem; 1998 Mar; 41(6):775-7. PubMed ID: 9526553 [No Abstract] [Full Text] [Related]
44. NO inhibitors and septic shock. Cohen J; Silva A Lancet; 1992 Mar; 339(8795):751. PubMed ID: 1347627 [No Abstract] [Full Text] [Related]
49. Vascular biology: relevance of nitric oxide in vascular and nonvascular tissue with normal and decreased renal function. Blantz RC Blood Purif; 1994; 12(1):30-5. PubMed ID: 7527221 [TBL] [Abstract][Full Text] [Related]
50. Nitric oxide: moving towards the clinic. Kilbourn RG Mol Med Today; 1996 Aug; 2(8):324. PubMed ID: 8796916 [TBL] [Abstract][Full Text] [Related]
51. Overproduction of nitric oxide in cytokine-mediated and septic shock. Kilbourn RG; Griffith OW J Natl Cancer Inst; 1992 Jun; 84(11):827-31. PubMed ID: 1375655 [No Abstract] [Full Text] [Related]
52. Relaxin inhibits histamine release from mast cells: involvement of nitric oxide production. Masini E; Di Bello MG; Bani D; Bigazzi M; Bani Sacchi T; Mannaioni PF Inflamm Res; 1995 Apr; 44 Suppl 1():S12-3. PubMed ID: 8520977 [No Abstract] [Full Text] [Related]
53. Inhibition of NO synthesis in septic shock. Hotchkiss RS; Karl IE; Parker JL; Adams HR Lancet; 1992 Feb; 339(8790):434-5. PubMed ID: 1346700 [No Abstract] [Full Text] [Related]
54. Inhibition of nitric oxide synthase during sepsis: revival because of isoform selectivity? Stahl W; Matejovic M; Radermacher P Shock; 2010 Sep; 34(3):321-2. PubMed ID: 20601934 [No Abstract] [Full Text] [Related]
55. Modulating the L-arginine-nitric oxide pathway in septic shock: choosing the proper point of attack. Fink MP Crit Care Med; 1999 Sep; 27(9):2019-22. PubMed ID: 10507634 [No Abstract] [Full Text] [Related]
56. Drugs which modulate nitric oxide homeostasis are likely to provide therapeutic benefit in cardiovascular disease. Thiemermann C Cardiovasc Res; 1993 Dec; 27(12):2104. PubMed ID: 8313413 [No Abstract] [Full Text] [Related]
57. Nitric oxide synthase inhibition in septic shock--a question of the right time, the right drug, and the right model? Bone HG Crit Care Med; 1998 Dec; 26(12):1945-7. PubMed ID: 9875895 [No Abstract] [Full Text] [Related]
58. Inhibition of NO synthesis in septic shock. Geroulanos S; Schilling J; Cakmakci M; Jung HH; Largiader F Lancet; 1992 Feb; 339(8790):435. PubMed ID: 1346701 [No Abstract] [Full Text] [Related]
59. Acute purulent sinusitis triggered by topical nasal nitric oxide synthase inhibition. Lundberg JO Am J Respir Crit Care Med; 2005 Aug; 172(4):512-3. PubMed ID: 16081564 [No Abstract] [Full Text] [Related]